VX-659 + Tezacaftor + Ivacaftor - A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
North Shore University Hospital CCOP Manhasset, NY, NY USA
jlittlet@pop.uky.edu.test
